AlzChem Group 향후 성장

Future 기준 점검 4/6

AlzChem Group (는) 각각 연간 17.4% 및 8.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 26.2% 로 예상됩니다.

핵심 정보

17.4%

이익 성장률

17.40%

EPS 성장률

Chemicals 이익 성장	36.2%
매출 성장률	8.5%
향후 자기자본이익률	26.24%
애널리스트 커버리지	Low
마지막 업데이트	03 Sep 2025

최근 향후 성장 업데이트

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 02

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05

Recent updates

Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Sep 13

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Aug 20

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 02

AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 22

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Mar 03

Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)

Feb 19

Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position

Feb 17 Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.

AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

Nov 14

AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

Oct 27

When Should You Buy AlzChem Group AG (ETR:ACT)?

Oct 18

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Nov 01

Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

Oct 12

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

May 06

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05

AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 05

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

Mar 04

이익 및 매출 성장 예측

XTRA:ACT - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	722	89	54	95	5
12/31/2026	629	70	70	136	5
12/31/2025	576	60	42	131	5
6/30/2025	566	58	41	113	N/A
3/31/2025	559	56	72	121	N/A
12/31/2024	563	54	62	105	N/A
9/30/2024	560	50	70	103	N/A
6/30/2024	551	46	64	97	N/A
3/31/2024	546	39	73	96	N/A
12/31/2023	546	35	52	73	N/A
9/30/2023	533	30	25	55	N/A
6/30/2023	554	28	24	53	N/A
3/31/2023	570	30	-15	12	N/A
12/31/2022	550	30	-33	-4	N/A
9/30/2022	534	29	-25	4	N/A
6/30/2022	487	28	-28	0	N/A
3/31/2022	454	27	3	29	N/A
12/31/2021	429	28	14	43	N/A
9/30/2021	420	27	11	40	N/A
6/30/2021	406	26	34	63	N/A
3/31/2021	397	23	14	48	N/A
12/31/2020	386	20	20	49	N/A
9/30/2020	370	16	10	52	N/A
6/30/2020	389	17	11	53	N/A
3/31/2020	387	17	20	54	N/A
12/31/2019	385	18	2	44	N/A
9/30/2019	389	19	2	42	N/A
6/30/2019	380	18	-18	22	N/A
3/31/2019	380	20	N/A	33	N/A
12/31/2018	383	23	N/A	35	N/A
9/30/2018	380	22	N/A	24	N/A
6/30/2018	398	32	N/A	31	N/A
3/31/2018	364	21	N/A	23	N/A
12/31/2017	361	20	N/A	31	N/A
9/30/2017	356	22	N/A	31	N/A
12/31/2016	333	15	N/A	33	N/A
9/30/2016	331	12	N/A	39	N/A
12/31/2015	329	15	N/A	30	N/A
12/31/2014	298	14	N/A	18	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ACT 의 연간 예상 수익 증가율(17.4%)이 saving rate(1.4%)보다 높습니다.

수익 vs 시장: ACT 의 연간 수익(17.4%)이 German 시장(16.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: ACT 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: ACT 의 수익(연간 8.5%)이 German 시장(연간 6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ACT 의 수익(연간 8.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ACT의 자본 수익률은 3년 후 26.2%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/05 20:13
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

AlzChem Group AG는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Volker Bosse	Baader Helvea Equity Research
Konstantin Wiechert	Baader Helvea Equity Research
Gerhard Orgonas	Berenberg

AlzChem Group 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 14% to €154

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target increased by 15% to €135

AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025

Price target increased by 12% to €85.18

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

Recent updates

AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025

Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Price target increased by 14% to €154

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target increased by 15% to €135

Now 26% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 18%

AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Now 22% overvalued after recent price rise

Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

New minor risk - Share price stability

AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025

Investor sentiment improves as stock rises 17%

What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025

Upcoming dividend of €1.80 per share

Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?

Investor sentiment improves as stock rises 16%

AlzChem Group AG, Annual General Meeting, May 08, 2025

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case

Investor sentiment improves as stock rises 17%

Price target increased by 12% to €85.18

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)

Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position

Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025

AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025

AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023)

AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025

AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

Price target increased by 13% to €71.78

When Should You Buy AlzChem Group AG (ETR:ACT)?

Price target increased by 7.7% to €66.03

Investor sentiment improves as stock rises 20%

Now 23% overvalued

Investor sentiment deteriorates as stock falls 16%

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Price target increased by 13% to €61.30

Price target increased by 9.4% to €57.05

Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023)

AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 9.4% to €54.05

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Price target increased by 15% to €49.40

AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023)

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Dividend increased to €1.20

Investor sentiment improves as stock rises 17%

AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 7.9% to €37.35

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.9% to €35.60

Price target increased by 9.1% to €34.63

AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024

Price target increased by 9.3% to €33.00

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching